Sinew Pharma Inc.
Diamond Biofund is the nutrient and
cultivator to the biotech startups
– Chairman and President, MD, PhD., Kai-Min Chu, Sinew Pharma –
Mr. Hu, Shih once said, ” As you sow, so will you reap.” This is an apt description of the biotech venture capital industry. In addition to a large amount of capital injection, biotech venture capitals devote more resources than the general industry, including upgrading technology and business strategies, enabling the biotechnology industry to thrive. Diamond Biofund is the nourisher and cultivator of new biotech ventures. From the start-up stage of Sinew Pharma all the way to the capital market, Diamond Biofund has always given Sinew the strongest support. In the future, Sinew will uphold the goal of solving unmet clinical needs and leading Sinew to the world.
Introduction
Sinew Pharma was founded in June 2014 with the goal of developing innovative drugs to address important unmet medical needs. The company is currently focused on two major disease areas: 1) Metabolic dysfunction–associated steatohepatitis (MASH) and its associated conditions, such as liver cirrhosis and liver cancer. 2) Acetaminophen-induced hepatotoxicity and severe liver injury.
Driven by the demands in these disease areas, Sinew Pharma is developing a novel drug for MASH and the world’s first new acetaminophen with high liver safety. By addressing these critical health challenges, SINEW aspires to become a globally leading pharmaceutical company.
Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations, and one serves as an antidote for acetaminophen overdose.